Search clinical trials for: G1

Total 327 results

Brugmann University Hospital

Recruiting

Does the Thrombin Generation Test Performed During the Pharmacokinetic Profile of the Substitutive Factor VIII Bring Benefits to the Personalized Treatment of Pediatric Patients and Adult Hemophilia A Patients Under Prophylaxis ?

Hemophilia

Belgium
Mansoura University

Completed

Biliary Cannulation During Endoscopic Retrograde Cholangiopancreatography: Precut Versus Conventional Cannulation (ERCP)

Jaundice, Obstructive

Egypt
Federal University of Rio Grande do Sul

Unknown

Effect of Supragingival Control Versus Supra- and Subgingival Control in the Periodontal Health During the Maintenance

Periodontitis

Brazil
M.D. Anderson Cancer Center

Completed

IUdR/BUdR Cell Cycle Labelling

Hematologic Malignancies

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Bangabandhu Sheikh Mujib Medical University, Dhaka...

Recruiting

Study of Comparative Effectiveness of Prucalopride and Lubiprostone in Constipation Predominant Irritable Bowel Syndrome

Patient Satisfaction

Bangladesh
Prince of Songkla University

Completed

Short Duration Versus Fourteen Days Antibiotic in Common Bile Duct Cholangitis

Common Bile Duct Calculi | Acute Cholangitis

Thailand
University of Michigan
Dentsply International

Completed

Efficacy Study of Articaine Versus Lidocaine as Supplemental Infiltration in Inflamed Molars (ARTIC)

Irreversible Pulpitis

United States
Federal University of Paraíba

Completed

Evaluation of a Low Fluoride Dentifrice for Caries Control

Dental Caries

Brazil
Singapore National Eye Centre
Allergan

Unknown

Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study

Glaucoma, Angle-Closure

Singapore
Mansoura University

Completed

Early Versus Late Cholecystectomy After Clearance of Common Bile Duct Stones (ERCP)

Gallbladder and Bile Duct Calculi
University of Zurich
GlaxoSmithKline

Completed

Psychophysical Characterization and Brain Correlates of Dentine Hypersensitivity

Dentine Hypersensitivity

Switzerland
G1 Therapeutics, Inc.

Active, not recruiting

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Triple Negative Breast Cancer

United States
Damascus Hospital
UNIPHARMA. Universal Pharmaceutical Industries; Ibn Alhaytham Pharma. Industries...

Unknown

Comparison Efficacy of 14-day Triple Therapy: Clarithromycin vs. Levofloxacin on Eradication of H. Pylori

Helicobacter Pylori Gastrointestinal Tract Infection

Syrian Arab Republic
Assiut University

Not yet recruiting

Gliflozins on HF in Regurgitant Rheumatic Heart

Heart Failure | Rheumatic Heart Disease
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Prince of Songkla University

Terminated

Endoscopic Biliary Drainage in Malignant High Grade Biliary Stricture

Malignant Biliary Stricture

Thailand
Virginia Commonwealth University

Terminated

Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Pediatric

Apical Periodontitis | Caries,Dental

United States
Virginia Commonwealth University

Withdrawn

Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Endodontics

Apical Periodontitis | Caries,Dental
Ain Shams University

Completed

A Comparison of 4% Articaine Versus 0.5%Bupivacaine for Ambulatory Surgery Under Supraclavicular Block

Upper Limb Surgery | Hand Surgery

Egypt
Shanghai First Maternity and Infant Hospital

Unknown

The Use of High-energy Digestible Food in Women Undergoing Caesarean Section

Caesarean Section

China
Vanderbilt University
Sanofi

Completed

Insulin Exposure and Glucose Response to Meals in Type 1 Diabetic Subjects Administered Two Different Insulin Regimens Compared to the Endogenous Insulin Exposure and Glucose Response to Meals In Healthy Adult Controls

Type 1 Diabetes
Sanofi

Completed

Insulin Glulisine, Diabetes Mellitus Type 1

Diabetes Mellitus, Type 1

Russian Federation
Sanofi

Completed

Dose-Exposure-Response in Type 1 Diabetes Mellitus

Diabetes Mellitus, Type I

Germany
Mansoura University

Completed

Management of Borderline Common Bile Duct Stone (CBDS)

Common Bile Duct Stone
Vaxart

Completed

Norovirus Challenge Study (G1-1 Challenge)

Norovirus Infections

United States
National Cancer Institute (NCI)

Active, not recruiting

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Metastatic Digestive System Neuroendocrine Tumor G1 | Metastatic Carcinoid Tumor | Recurrent Digestive System Neuroendocrine Tumor G1 | Regional Digestive System Neuroendocrine Tumor G1 | Midgut Neuroendocrine Tumor G1 | Foregut Neuroendocrine Tumor | Hindgut Neuroendocrine Tumor | Neuroendocrine...

Canada, United States
National Cancer Institute (NCI)

Active, not recruiting

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Carcinoid Tumor | Neuroendocrine Neoplasm | Colorectal Neuroendocrine Tumor G1 | Gastric Neuroendocrine Tumor G1 | Neuroendocrine Tumor G2

United States
G1 Therapeutics, Inc.

Completed

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

Breast Cancer | Triple Negative Breast Cancer

United States
G1 Therapeutics, Inc.

Completed

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer

Spain, United States, Georgia, France, Moldova, Republic of, Hungary, Poland
Menoufia University

Completed

Platelet Rich Plasma Injection Versus Surgical Fixation Procedure in Management of Spondylolisthesis grade1.

Degenerative Spondylolisthesis G1

Egypt
G1 Therapeutics, Inc.

Recruiting

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Extensive-stage Small-cell Lung Cancer

Spain, Greece, Turkey, Poland, Georgia, Austria, Belgium, Bulgaria, Germany, Hungary
G1 Therapeutics, Inc.

Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab (PRESERVE3)

Bladder Cancer | Urothelial Carcinoma | Chemotherapy-induced Neutropenia | Myelosuppression Adult | Metastatic Bladder Cancer

Hungary, Spain, United States, France, Georgia
G1 Therapeutics, Inc.

Completed

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Non-small Cell Lung Cancer

United States
G1 Therapeutics, Inc.

Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) (PRESERVE 4)

NSCLC | Lung Cancer | Metastatic Non-Small Cell Lung Cancer

United States
G1 Therapeutics, Inc.

Completed

Safety, Pharmacokinetic and Pharmacodynamic Study of the CDK 4/6 Inhibitor G1T28-1

Healthy Volunteers

Netherlands
G1 Therapeutics, Inc.

Active, not recruiting

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) (PRESERVE 2)

Breast Cancer | TNBC - Triple-Negative Breast Cancer

United States, Spain, China, France, Australia, Georgia, Poland, Bulgaria, Moldova, Republic of, Russian Federation, Ukraine
G1 Therapeutics, Inc.

Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): (PRESERVE1)

Colorectal Cancer Metastatic | Chemotherapeutic Toxicity | Myelosuppression-Adult

China, Spain, United States, Hungary, United Kingdom, Poland, Ukraine, Italy
G1 Therapeutics, Inc.

Active, not recruiting

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Breast Cancer | Breast Neoplasm | Carcinoma, Ductal, Breast

United Kingdom, Bulgaria, Georgia, Moldova, Republic of
G1 Therapeutics, Inc.

Completed

G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Stage IV Breast Cancer | Carcinoma, Ductal, Breast | Breast Cancer Female

United States, Belgium, Bulgaria, Georgia, Netherlands, Moldova, Republic of, Ukraine
G1 Therapeutics, Inc.

Terminated

Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy

Small Cell Lung Cancer

United States, Croatia, Belgium, Slovakia, Bosnia and Herzegovina, North Macedonia, Serbia, Slovenia
G1 Therapeutics, Inc.

Terminated

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

Breast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasms

United States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
G1 Therapeutics, Inc.

Completed

First-in-Human Safety, PK, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy Volunteers

Healthy Volunteers

Netherlands
OPKO Health, Inc.

Completed

A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1

Type 2 Diabetes

United States
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III

Chronic Hepatitis C
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

Chronic Hepatitis C
OPKO Health, Inc.

Completed

A Study in Type 1 Diabetic Patients With Repeated Doses of E1 in Combination With G1

Type 1 Diabetes

United States
Damascus Hospital

Completed

Comparing Efficacy of 14-day Therapy Doxycycline With Bismuth Subsalicylate Versus Levofloxacin With Tinadizole on Treatment Helicobacter Pylori

Helicobacter Pylori Infection

Syrian Arab Republic
Tongji Hospital

Unknown

A Pilot Study of Sildenafil in COVID-19

COVID-19

China
Aveni Foundation

Withdrawn

CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19 (CORONA)

COVID-19 | Acute Respiratory Distress Syndrome | Cytokine Storm

Search clinical trials for: G1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations